Status:
COMPLETED
Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over
Lead Sponsor:
Novartis
Conditions:
Healthy Volunteers
Eligibility:
All Genders
60+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin.
Eligibility Criteria
Inclusion
- Males and females aged 60 and over
- United States English as a primary language
- Given written informed consent by signing and dating an informed consent form prior to study entry
Exclusion
- Current diseases in which the use of anti-cholinergic drugs is contraindicated, including the use of drugs with anti-cholinergic effects
- Volunteers with history of urinary retention or current bladder outlet obstruction, as determined by the investigator
- Other protocol defined inclusion/exclusion criteria may apply.
- \- Current use of drugs known to effect memory and cognition Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2005
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00170768
Start Date
February 1 2005
End Date
May 1 2005
Last Update
January 23 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington Neuropsychological Institute LLC Georgetown
Washington D.C., District of Columbia, United States, 20016